Skip to content
    • Why Australia
    • Regulatory and ethics pathway
    • R&D tax incentive overview
    • Data Acceptability
    • Full-service in-house
    • Clinical Phases
    • Data Management
    • Avi.Suite
    • Biostatistics
    • Consulting
    • Imaging Core Lab
    • Radiopharmaceutical Trials
    • Nuclear Medicine
    • Dosimetry
    • Oncology
    • Haematology
    • Radiopharmaceuticals
    • Dermatology
    • Healthy Volunteers
    • Cell and Gene/Complex Therapeutics
    • Central nervous system
  • About Avion CRO
  • News & Insights
  • Contact
  • The Australian Advantage
    • Why Australia
    • Regulatory and ethics pathway
    • R&D tax incentive overview
    • Data Acceptability
  • Capabilities
    • Full-service in-house
    • Clinical Phases
    • Data Management
    • Avi.Suite
    • Biostatistics
    • Consulting
  • Imaging & Radiopharma
    • Imaging Core Lab
    • Radiopharmaceutical Trials
    • Nuclear Medicine
    • Dosimetry
  • Therapeutic Areas
    • Oncology
    • Haematology
    • Radiopharmaceuticals
    • Dermatology
    • Healthy Volunteers
    • Cell and Gene/Complex Therapeutics
    • Central nervous system
  • About Avion CRO
  • News & Insights
  • Contact

Latest insight

  • Powering the Future of Precision Medicine with Radiopharmaceuticals: Where Science Meets Innovation
    Powering the Future of Precision Medicine with Radiopharmaceuticals: Where Science Meets Innovation
    Read article: Powering the Future of Precision Medicine with Radiopharmaceuticals: Where Science Meets Innovation
Start a study
  • Terms of Use
  • Privacy Policy
Avion CRO

Avion CRO

Data Acceptability

START A STUDY
  1. Home
  2. The Australian Advantage
  3. Data Acceptability

Data regulators accept, worldwide

Remove the biggest question mark before it’s asked.

01

Global standards, as standard

Australian trials run to ICH GCP, the same standard the FDA and EMA expect, and Avion CRO collects data in a CFR Part 11 compliant manner.

02

Routinely accepted

Data from Australian studies is routinely used in FDA, EMA and other global regulatory submissions.

03

Nothing needs repeating

Early-phase data generated in Australia feeds directly into later-phase programmes anywhere in the world, so an Australian start never becomes a detour.


Common Questions

Yes, routinely. Australian trials run to ICH GCP, the same standard the FDA expects, and data from Australian studies is regularly used in FDA, EMA and other global regulatory submissions.

 

No. Early-phase data generated in Australia to ICH GCP feeds directly into later-phase programmes anywhere in the world.

 

Work With Us

Planning your next study?

Tell us where your programme is up to and we’ll tell you, honestly, how we can help.

Talk to us about your next study
Avion Footer Logo

(+61) 1300 131 548

info@avionmedical.com.au

Navigation

  • The Australian Advantage
  • Capabilities
  • Imaging & Radiopharma
  • Therapeutic Areas

Company

  • About Us
  • Careers
  • News & Insights
  • Contact

Office Location

141 Camberwell Road
Hawthorn East VIC
3123, Australia

  • LinkedIn

© 2026

Avion Medical Pty Ltd. All rights reserved

  • Terms of Use
  • Privacy Policy

Made by Mulberry